Karo Bio Selects Reaxys and Reaxys Medicinal Chemistry to Support Chemists in
Research and Development
AMSTERDAM, July 9, 2013
AMSTERDAM, July 9, 2013 /PRNewswire/ --
Comprehensive and relevant chemistry and bioactivity related content reduces
research timescales and supports rapid user adoption
Elsevier , a world-leading provider of scientific, technical and medical
information products and services, today announced that Karo Bio , a developer
of innovative drugs for large medical needs, has started to use Reaxys ® and
Reaxys® Medicinal Chemistry . Karo Bio has chosen the solutions to support its
chemists in their research and development objectives, ensuring they have
quick and easy access to state of the art chemistry information.
"Comprehensive content is critical to our chemists and the Reaxys solutions
give them more relevant results in a single search than other solutions could
offer," said Maria Sjöberg, Chief Scientific Officer at Karo Bio. "Not only do
our chemists have access to more data, including biological as well as
chemical information, but the content is more applicable to their research. We
expect the availability of the Reaxys Medicinal Chemistry information alone
will reduce research and development time by approximately 20 percent."
Reaxys, with its recent expansion of chemistry data and capabilities now
encompassing content of over 16,000 periodicals, is recognized by users as
having the deepest and richest fact-base of experimentally measured chemistry
data. Reaxys Medicinal Chemistry offers access to data from a vast repository
of peer-reviewed journal articles and patents and is interoperable with
Reaxys. Adding this content to Karo Bio's information sources means that
chemists will have readily available access to relevant information. That,
coupled with the flexibility of the search function and the way results are
presented, will enable chemists to more quickly identify and prioritize viable
compounds, helping reduce the time it takes to bring innovative drugs to
"Researchers in life sciences face an ever growing challenge in making
confident and successful decisions in a changing landscape," said Dr. Juergen
Swienty-Busch, Head of Product Management for Reaxys. "Karo Bio has a unique
knowledge of nuclear receptors as target proteins for the development of novel
pharmaceuticals. We are excited that the Reaxys solutions will play a part in
increasing the speed at which these projects to discover innovative compounds
come to fruition."
Reaxys and Reaxys Medicinal Chemistry are part of Elsevier Life Science
Solutions, a suite of interoperable, domain-specific, decision support tools
which span the discovery and development workflow; including ScienceDirect,
Scopus, TargetInsights, Pathway Studio, PharmaPendium, QUOSA and Embase.
For further information go to http://www.elsevier.com/reaxys .
About Karo Bio
Karo Bio is a pharmaceutical company focused on the research and development
of innovative drugs for large medical needs. The company runs a number of drug
development projects within the indication areas neuropsychiatry,
inflammation, autoimmune diseases and cancer. An important foundation for the
company's activities is its unique knowledge of nuclear receptors as target
proteins for the development of novel pharmaceuticals, as well as related
mechanisms of action. Karo Bio is based in Huddinge, Sweden, has around 43
employees and is listed on NASDAQ OMX Stockholm. http://www.karobio.com
Reaxys® is a workflow solution for research chemists. Offering a wealth of
experimentally validated information, Reaxys® combines reaction and substance
data in organic, organometallic, inorganic and physical chemistry with
synthesis planning. Researchers can get the information they need in a single
overview, from source publications carefully selected for their importance and
relevance to research chemists. Elsevier continues to engage with the
chemistry community to ensure that Reaxys® continues to reflect how chemists
think and work. For more information please visit Reaxys .
Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier
Properties SA and used under license.
Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including The Lancet and Cell , and close to 20,000 book titles, including
major reference works from Mosby and Saunders. Elsevier's online solutions
include ScienceDirect , Scopus , Reaxys , ClinicalKey and Mosby's Suite ,
which enhance the productivity of science and health professionals, and the
SciVal suite and MEDai's Pinpoint Review , which help research and health care
institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group plc , a world leading
provider of professional information solutions. The group employs more than
30,000 people, including more than 15,000 in North America. Reed Elsevier
Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed
Elsevier NV. Their shares are traded on the London, Amsterdam and New York
Stock Exchanges using the following ticker symbols: London: REL; Amsterdam:
REN; New York: RUK and ENL.
Media contact Liz Griffioen Elsevier +31-20-485-2247 L.Griffioen@elsevier.com
Press spacebar to pause and continue. Press esc to stop.